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Highlights  
- Concentrations from phase-1 study with CMS and AZT in combination with loading 
and maintenance dose  
- Bactericidal activity in serum spiked with colistin and AZT concentrations alone or 
combined 
- Combination of colistin with AZT increased serum bactericidal activity  
- Dosage of 2 MIU CMS + AZT 100mg q12 sufficient to treat infection with colistin-
susceptible strains 
- for infections with colistin-resistant strains the dosage should be higher 
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Abstract 
To examine the serum bactericidal activity of colistin-sulphate (CS) and azidothymidine (AZT) 
combinations, time-kill curves were performed in native and heat-inactivated human serum 
with five colistin-resistant and four colistin-susceptible Gram-negative strains. The serum 
samples were spiked according to the median and minimum plasma peak concentrations 
measured in a phase 1 clinical study, in which seven healthy subjects received 3-times (q12) 
1h-IV-infusions of 4, 2 and 2 million international units (MIU) colistin-methanesulfonate 
(CMS)  co-administered with 200, 100 and 100 mg AZT, respectively. This trial was 
performed to assess the pharmacokinetics and safety of CMS/AZT-combination therapy.  
Minimal bactericidal concentrations of CS in native, but not heat-inactivated serum, were 
strongly reduced compared to Mueller-Hinton-Broth for all tested Enterobacteriaceae, 
except one colistin-resistant (serum-resistant) strain. For colistin-susceptible strains, the 
minimum CS concentration after 2 MIU CMS dosage was already bactericidal in native and 
heat-inactivated serum. Median, but not minimum, CS concentrations after 2 MIU CMS 
dosage were sufficient to kill the serum-resistant, colistin-resistant E.coli strain in native 
serum. In heat-inactivated serum, even the median CS concentration after 2 MIU CMS 
dosage was not bactericidal for all colistin-resistant strains. In general, combinations with 
AZT accelerated killing of colistin-resistant E.coli or showed bactericidal activity even if the 
substances alone were not bactericidal. Thus, the combination with AZT potentiates the 
bactericidal effect of colistin against colistin-resistant E.coli strains. Although the dosage of 2 
MIU CMS plus AZT may be sufficient to treat infections with colistin-susceptible strains, for 
infections caused by colistin-resistant E.coli the dosing should be further optimized. 
 
Keywords: Colistin, Azidothymidine, combination therapy, serum bactericidal activity 
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Introduction 
Gram-negative bacteria, especially Enterobacteriaceae, are the major cause of both 
community and hospital-acquired urinary tract infections (UTI), which is worsened by the 
continuous antibiotic resistance emergence and a shortage of new antibiotics under 
development. The number of antimicrobial agents to medicate infections caused by 
antibiotic-resistant Enterobacteriaceae is limited, and the polymyxins such as colistin are 
considered the last resort treatment [1].  
Two different forms of colistin are available for clinical use, colistin sulphate (CS) and colistin 
methanesulfonate (CMS). CS is used for treatments of topical and gastrointestinal infections 
but is not used systemically as it causes undesirable side effects such as irritation at 
subcutaneous or intramuscular injection sites. CMS is preferred for parenteral and aerosol 
therapies [2] since it causes fewer adverse reactions than CS. In aqueous solutions, CMS 
undergoes hydrolysis to form a complex mixture of partially sulfomethylated derivatives as 
well as colistin [2]. Unfortunately, resistance to colistin is rapidly emerging [3]. The first 
discovery of the transmissible plasmid-mediated colistin resistance encoded by the 
mobilized colistin resistance (mcr-1) gene in China [4] rapidly followed by numerous reports 
of the plasmid-borne mcr-1 gene in animals, food and clinical samples worldwide [5]. Most 
importantly, the mcr-1 colistin resistance was clearly shown to coexist with other multiple 
drug resistant (MDR) genes, highlighting the possibility that pan-drug resistant bacterial 
strains are emerging [6]. Therefore, a different strategy is urgently required to preserve, 
restore or enhance the therapeutic potencies of existing antibiotics against resistant 
bacteria. Such strategies include repurposing marketed drugs, as these have known 
toxicology and pharmacology profiles, to interact synergistically with existing antibiotics.  
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Azidothymidine (AZT, zidovudine) is an antiretroviral drug, which is used in combination with 
other antivirals to prevent and to treat human immunodeficiency virus infection and 
acquired immune deficiency syndrome (HIV/AIDS) [7]. AZT acts antibacterial against 
Enterobacteriaceae [8]. Furthermore, a synergistic antibacterial activity between AZT and 
gentamicin or colistin was shown for Enterobacteriaceae strains recently [9, Hu et al. 
submitted, unpublished data]. 
The aim of this study was to determine the serum bactericidal activity of CS and AZT 
combinations against five colistin-resistant Escherichia coli strains as compared to colistin-
susceptible E. coli, Acinetobacter baumannii and Pseudomonas aeruginosa strains using 
concentrations of both drugs obtained from a phase 1 study [10].   
 
Material & Methods 
Ethical approval and conduct 
This ex-vivo annex trial is part of a randomized, double-blinded, placebo-controlled dose 
escalation study in healthy volunteers receiving multiple doses of IV CMS co-administrated 
with AZT performed in the phase 1 unit of the QuotientSciences, Nottingham, UK. The study 
was performed in accordance with ethical principles that have their origin in the Declaration 
of Helsinki, and are consistent with International Conference on Harmonization/Good 
Clinical Practice. The phase 1 study was registered with the European Clinical Trial database 
EudraCT (#2016-002767-34). 
 
Study design and plasma concentrations 
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Detailed safety information, laboratory test results and pharmacokinetic evaluations of this 
phase 1 study are presented elsewhere [10]. Seven volunteers received 3 times (q12) 1 h IV-
infusions of 4, 2 and 2 million international units (MIU) CMS co-administered with 200, 100 
and 100 mg AZT, respectively.  
Plasma samples were collected at different time points, were frozen immediately to -80 °C 
and kept at -80°C until analysis no longer than 4 weeks.  Samples were analysed by validated 
LC-MS/MS method [11]. Maximum, median and minimum plasma concentrations of colistin 
and AZT obtained at the end of the 1 h IV infusion of the 1st, 2nd and 3rd dose are presented 
in table 1. Concentrations of colistin were expressed in colistin base, whose molecular 
weight slightly differs from CS (colistin base – 1155.5; CS – 1400.7; corresponding to colistin 
B [12-13]). Therefore, we converted the obtained colistin base concentrations to CS (factor 
1.212), which were then used for spiking the serum in the time-kill curve determinations 
(table 1).  
 
Bacterial strains 
Five clinical isolates harbouring the colistin-resistance gene mcr-1 (table 2) were used. In 
addition two isolates from urine of patients with UTI, P. aeruginosa 1640801 and A. 
baumannii CDH102, both showing carbapenem-resistance and the reference strains, E. coli 
ATCC 25922 and P. aeruginosa ATCC 27853 were included in this study as colistin-susceptible 
strains.  
 
Determination of minimal inhibitory and bactericidal concentrations (MIC/MBC) 
MIC/MBC determinations were performed according to the CLSI- and EUCAST-Standards [15-
17]. Broth microdilution assay was used for determination of the MIC/ MBC of CS and AZT. 
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Cation-adjusted Mueller Hinton broth (CAMHB) (Sigma Aldrich) and human serum, 
originated from pooled plasma collected from male donors of the AB serotype, (Sigma 
Aldrich) were used. For heat-inactivation, the serum was incubated for 30 min at 56°C. Two-
fold serial dilutions of media CS were prepared in 96-well plates (polystyrene, Greiner Bio-
One, Frickenhausen, Germany). Final inocula, which were confirmed by actual plating, 
ranged from 2 – 8 x 105 CFU/ml. After incubation at 37°C for 20 ± 2 h in ambient air the 
optical density (OD) at 600 nm was measured using a Multiskan GO plate reader (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). The MIC was defined as the lowest 
concentration inhibiting growth (OD600 ≤ 0.1). For determination of MBCs, in a second step 3 
µl from each well of the overnight incubated 96-well plate were transferred onto 
IsoSensitest agar supplemented with 5% blood (Oxoid, Wesel, Germany) using an one-time 
inoculator (Dr. Brinkmann Floramed, Nürtingen, Germany). The plates were incubated 
overnight at 37°C. The number of colonies, subsequently grown, was used to determine the 
bactericidal endpoint. MBC was defined as a > 99.9% (> 3-log) reduction of the initially 
inoculated colony counts. All determinations were repeated at least three times. 
 
Time-kill curve 
Time-kill curve analyses were performed by culturing the test strains in native or heat-
inactivated serum in the presence of CS and AZT, alone and in combination. CS and AZT 
quantities corresponding to median and/or minimum plasma concentrations 1 h after 1st 
and 3rd dose obtained from the phase 1 study were used. Bacterial strains (inoculum ~ 5*105 
CFU/ml) were inoculated in native or heat-inactivated serum in polycarbonate tubes 
(Sarstedt, Nümbrecht, Germany) and were allowed to equilibrate for 30 min at 37°C. Earlier 
studies indicated much lower sticking of colistin to polycarbonate than to polystyrene (data 
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not shown). CS and AZT, alone or in combination, were added and tubes were incubated at 
37°C at 180 rpm. Samples were taken for determination of viable counts at 0, 15, 30, 60, 
120, 240, 360 and 1440 min after the substances have been added. Serial dilutions were 
prepared in sterile PBS and plated onto MHB-agar plates. The plates were incubated at 37°C 
for 20 h, when the numbers of colonies were determined. Kill curves were constructed by 
plotting the log10 CFU/ml over 24 h. The detection limit was ~ 1*102 CFU/ml. Time-kill 
curves were performed once for each strain.  
 
Results 
Minimal inhibitory and bactericidal concentrations 
The MICs of CS measured in CAMHB ranged from 4 to 8 mg/l for the mcr-1 positive strains, 
which are classifying them as colistin resistant according to EUCAST criteria [18]. The MIC 
values of CS in CAMHB for E. coli ATCC 25922, P. aeruginosa ATCC 27853, P. aeruginosa 
1640801 and A. baumannii CDH102 ranged from 0.375 -1 mg/l classifying them as colistin 
susceptible (table 3). MBC values of CS in heat-inactivated serum are almost equal to those 
in CAMHB. In contrast, MBC values in native serum were considerably lower for E. coli ATCC 
25922 and for the mcr-1 positive E. coli strains except for E. coli Af49.  For P. aeruginosa 
ATCC 27853, P. aeruginosa 1640801 and A. baumannii CDH102 MBCs values in native serum 
only differ in one dilution step compared to CAMHB.  E. coli Af40, Af49, CDF1 and CDF8 as 
well as P. aeruginosa ATCC 27853, P. aeruginosa 1640801 and A. baumannii CDH102 showed 
MBC values of AZT between 8 - >16 mg/l in native serum, whereas MBC values of E. coli 
ATCC 25922 and E. coli Af23 were 0.25 mg/l and 0.5 mg/l, respectively. The MBC values of 
AZT in heat-inactivated serum ranged between 32 - >32 mg/l for all strains tested. 
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Time-kill curve 
To determine the serum antibacterial activity time-kill curve experiments were performed in 
native and heat-inactivated human serum spiked with CS and AZT, alone and in combination, 
using median and minimum plasma concentrations obtained 1 h after 1st and 3rd dose (table 
1).  
Median 1st and 3rd dose concentrations of CS were sufficient to kill E. coli Af49 in native 
serum, whereas minimum 3rd dose concentration just led to a slightly delayed growth (figure 
1). Adding AZT alone reduced bacterial numbers in a concentration-dependent manner for 
up to 6 h with a regrowth afterwards. Combination of CS with AZT led to complete killing of 
E. coli Af49 after at least 6 h for all concentrations tested in native serum (figure 1). For all 
other colistin-resistant and susceptible strains tested, the minimum 3rd dose concentration 
of CS was sufficient to kill the bacteria within 0.25 h and 4 h in native serum. It was also 
observed, that native serum by itself had an inhibitory or even a bactericidal effect in the 
first few hours for some of the tested strains (figure 2-3).  
Since a bactericidal activity of native serum has been shown to be heat-labile [19], time-kill 
curve experiments were also performed in heat-inactivated serum. In heat-inactivated 
serum, the minimum 3rd dose concentration of CS was not sufficient to kill any of the 
colistin-resistant strains but was adequate to eliminate all colistin-susceptible strains tested 
within 2 h (figure 4-5). AZT barely affected the bacterial growth at this concentrations. 
Combinations of CS with AZT were not beneficial for colistin-susceptible strains but had 
some bacteriostatic activities against colistin-resistant strains (figure 4-5). Three of the five 
colistin-resistant strains were at least restricted in growth or even killed by the median 3rd 
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dose concentration of CS in heat-inactivated serum. Combinations of AZT with CS showed 
bactericidal or at least bacteriostatic activities for all strains tested (figure 4). The median 1st 
dose concentration of CS was bactericidal or at least bacteriostatic for all colistin-resistant E. 
coli in heat-inactivated serum. Combination of AZT with CS accelerated the killing of the 
bacteria or showed bactericidal activity at all as compared to the individual substances alone 
(figure 4).  
 
Discussion  
This ex-vivo annex study was carried out as part of a phase 1 study in healthy volunteers 
[10]. The drug combination was well tolerated, with only transient and manageable 
gastrointestinal events with mild severity seen in this subgroup of healthy volunteers. The 
trial evaluated bactericidal activity of plasma concentrations obtained during IV-treatment 
with CMS in combination with AZT. The targeted bacteria were mcr-1 positive colistin-
resistant E. coli strains, which were compared to colistin-susceptible strains.  
The median MIC and MBC of colistin in CAMHB for the four mcr-1 positive E. coli strains 
ranged from 8-32 mg/l classifying them as resistant according to EUCAST criteria [18]. MBC 
values of colistin in heat-inactivated serum were comparable to those in CAMHB. In contrast, 
MBC values in native serum were noticeably lower for the E. coli but not for P. aeruginosa 
and A. baumannii strains. Furthermore, native serum on its own negatively affects the 
growth of some of the tested strains. The complement system in the human serum could 
eliminate bacteria by the formation of membrane-attack-complexes, which increase 
bacterial cell wall permeability [20]. The complement activity is heat-labile [19], which can 
be confirmed by comparison of the control sample growth in native or in heat-inactivated 
serum in our time-kill curve data. In these serum-sensitive strains, weakening the bacterial 
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membrane integrity by the complement system, even without killing the bacteria, could 
enhance the effectiveness of colistin. By adding 20% human serum to broth, a synergism 
between serum and the antibacterial activity of colistin was shown previously [21]. 
Nevertheless, serum-resistant strains, such as E. coli Af49 and A. baumannii CDH102, which 
can grow normally in native serum, showed comparable MBCs in native serum and CAMHB.     
For in vitro kill-curve assays the measured CB concentrations were converted to CS 
concentrations using a factor of 1.212, corresponding to the differences in molecular 
weights of CB B and CS B. Since colistin is a mixture of colistin A and B, molecular weights 
corresponding to colistin A or an average of A and B (CB – 1169.5/ CS – 1414.7 or CB – 
1162.5/ CS - 1407.7 [12-13]) could have been used as well. The conversion factors, however, 
would differ by only ≤ 0.25%, corresponding to a range of 10-20µg/l, which is negligible. 
Time-kill curve assays showed that the minimum plasma concentrations of colistin (1.26 
mg/l) after 2 MIU CMS dosage reached at least minimal bactericidal concentrations for 
colistin-susceptible and carbapenem-resistant strains. Due to the human serum’s synergistic 
activity, even minimum CS concentrations after 2 MIU dosage were sufficient to kill the 
serum-sensitive colistin-resistant strains in native serum. In contrast, inactivating the heat-
labile complement system means that even the median CS plasma concentration after 4 MIU 
CMS dosage (4.91mg/l) was not able to kill all colistin-resistant strains. Thus, it can be 
assumed that plasma concentrations of CS obtained after a 4 MIU dosage of CMS may not 
be sufficient to kill serum-resistant colistin-resistant bacteria. Nevertheless, the combination 
with AZT accelerated killing of the bacteria or acted bacteriostatically/ bactericidally when 
CS alone was not bactericidal within 4 h or even at all.  
The antibacterial activity of AZT can be traced back to the inhibition of the replicative DNA-
synthesis after incorporation of azidothymidine-triphosphate [7]. This effect is often only 
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temporary. Mutations resulting in a lack of thymidine kinase lead to an increased resistance 
against azidothymidine [7]. AZT resistant strains may emerge also in vivo, but no cross-
resistance to other antimicrobial agents has been seen with AZT [9, 22]. AZT did not affect 
the growth of Pseudomonas and Acinetobacter strains as these species often naturally lack a 
thymidine kinase [23-24]. Furthermore, the combination with colistin was not conducive to 
the killing of these strains.  
Since medium CS plasma concentrations reached after 1h-IV-infusions of 4 MIU CMS are not 
sufficient to kill all colistin-resistant strains, the dosage of colistin may need to be increased 
as one option. Although nephrotoxicity associated with colistin is not as toxic as originally 
thought [25-26], an adverse effect must still be considered when administering increasing 
colistin dosages. This risk of nephrotoxicity did not appear to be related to daily doses of 
CMS, but rather to the total cumulative dose [27]. The risk of nephrotoxicity, although 
mostly reversible, could even be increased by factors such as concomitant use of a 
calcineurin inhibitor, hyperbilirubinemia, and hypoalbuminemia [25-26]. In contrast, 
nephrotoxicity is not described for AZT [28]. Therefore, as an alternative to increasing 
colistin dosages, combination therapy with lower CMS dose combined with an optimized 
AZT dosage should be developed further.  
 
Conclusion 
This ex-vivo annex study provided evidence that a combination of colistin with AZT 
potentiates the bactericidal effect of colistin against colistin-resistant E. coli strains. This 
result needs to be confirmed in human studies. Although AZT and colistin plasma 
concentrations reached after one-hour infusion of 2 MIU CMS combined with 100 mg AZT 
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are sufficient for the treatment of colistin-susceptible, even carbapenem-resistant, strains, 
the dosage should be further optimized for infections caused by colistin-resistant E. coli.  
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Figure 1 Time-kill curves in native serum with E. coli Af49  
Bacteria were inoculated with 5*105 CFU/ml in native serum. After adding colistin sulphate (CS) and 
azidothymidine (AZT) alone or in combination according to the median and minimum plasma 
concentrations after 1st and/or 3rd dose (1h after IV infusion) bacteria were incubated at 37°C and 
180rpm. Ctrl – control without any addition 
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Figure 2 Time-kill curves in native serum of colistin-resistant E. coli strains using minimum 3rd dose 
concentrations 
Bacteria were inoculated in native serum. After adding colistin sulphate (CS) and azidothymidine 
(AZT) alone or in combination according to the minimum plasma concentrations after 3rd dose (1h 
after IV infusion) bacteria were incubated at 37°C and 180rpm. Ctrl – control without any addition 
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Figure 3 Time-kill curves in native serum of colistin-susceptible strains using minimum 3rd dose 
concentrations 
Bacteria were inoculated in native serum. After adding colistin sulphate (CS) and azidothymidine 
(AZT) alone or in combination according to the minimum plasma concentrations after 3rd dose (1h 
after IV infusion) bacteria were incubated at 37°C and 180rpm. Ctrl – control without any addition 
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Figure 4 Time-kill curves in heat-inactivated serum of colistin-resistant strains 
Bacteria were inoculated in heat-inactivated serum. After adding colistin sulphate (CS) and 
azidothymidine (AZT) alone or in combination according to the median and minimum plasma 
concentrations after 1st and/or 3rd dose (1h after IV infusion) bacteria were incubated at 37°C and 
180rpm. Ctrl – control without any addition 
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Figure 5 Time-kill curves in heat-inactivated serum of colistin-susceptible strains with minimum 3rd 
dose concentrations  
Bacteria were inoculated in heat-inactivated serum. After adding colistin sulphate (CS) and 
azidothymidine (AZT) alone or in combination according to the minimum plasma concentrations after 
3rd dose (1h after IV infusion) bacteria were incubated at 37°C and 180rpm. Ctrl – control without any 
addition 
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TABLE 1 Plasma concentrations of colistin and AZT obtained 1 h after dosage 
 Colistin [mg/l] AZT [mg/l] 
 CB ≙CS 
 1st dose 
minimum 2.83 3.42 1.42 
median 4.06 4.91 1.84 
maximum 5.19 6.28 2.87 
 2nd dose 
minimum 2.03 2.46 0.44 
median 2.64 3.19 0.65 
maximum 2.98 3.61 0.81 
 3rd dose 
minimum 1.27 1.54 0.38 
median 2.62 3.17 0.68 
maximum 3.19 3.86 1.08 
 
 
 
TABLE 2 Features of the mcr-1 positive E. coli isolates 
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E. coli 
Af23 
IncI2/ 70 10 Human 
blood 
AMX-CIP-SXT-
TET 
blaTEM-1 ZA [14] 
E. coli 
Af40 
IncI2/ ND 57 Human 
wound 
AMX-CTX-CIP-
SXT-TET-CHL-FOS 
blaCTX-M-55 + 
fosA3 + tetR 
ZA [14] 
E. coli 
Af49 
ND/ ND 226 Human 
urine 
AMX-CTX-CIP-
SXT-TET-CHL-FOS 
blaCTX-M-55 + 
fosA3 + tetR 
ZA [14] 
E. coli 
CDF1 
IncFIB/ 90 3077 Human 
blood 
AMX-SXT-TET-
CIP-GEN 
blaTEM-1 CH - 
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E. coli 
CDF8 
Incx4/ 30 167 Human 
blood 
AMX-CTX-CIP blaCTX-M CD - 
AMX – Amoxicillin; CHL – Chloramphenicol; CIP – Ciprofloxacin; CTX – Cefotaxime; FOS – Fosfomycin; GEN – Gentamicin; 
KAN – Kanamycin; SXT – Trimethoprim/Sulfamethoxazole; TET – Tetracycline, ZA – South Africa; CH – Switzerland; ND – not 
determined  
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TABLE 3 Median (range) MIC values of CS in CAMHB and MBC values of CS and AZT in CAMHB, 
native and heat-inactivated serum 
 CAMHB  CS 
MIC/MBC 
Serum  
MBC 
Heat-inactivated serum 
MBC 
 MIC CS 
(mg/l) 
MBC CS 
(mg/l) 
CS 
(mg/l) 
AZT 
(mg/l) 
CS 
(mg/l) 
AZT 
(mg/l) 
E. coli Af23 
8  
(4-8) 
8 
 (4-32) 
0.25 
(0.06-0.25) 
0.5 
 (0.25-1) 
4 
(4-8) 
32 
(16->32) 
E. coli Af40 
8  
(4-8) 
16  
(16-32) 
0.50  
(0.13-1) 
>16  
(16->16) 
4 
(4-8) 
>32 
(>32) 
E. coli Af49 
8 
 (8-16) 
16  
(8-32) 
8  
(2-8) 
>16  
(16->16) 
8 
(8) 
>32 
(>32) 
E. coli CDF1 
4 
 (4-16) 
8  
(4-16) 
0.5 
 (0.5-1) 
16  
(8->16) 
8 
(4-8) 
32 
(16-32) 
E. coli CDF8 
8  
(4-16) 
16  
(4-16) 
2  
(0.06-2) 
8  
(1-16) 
8 
(8-16) 
>32 
(32->32) 
E. coli 
ATCC25922 
1 
(0.25-1) 
1 
(0.25-1) 
0.13  
(0.06-0.13) 
0.25 
(0.25-1) 
2  
(1-2) 
32 
(32->32) 
P. aeruginosa 
ATCC27853 
1  
(0.5-2) 
1 
 (0.5-2) 
0.5 
 (0.5-2) 
>16  
(>16) 
4  
(4-8) 
>32 
(>32) 
P. aeruginosa 
1640801 
0.375 
(0.25-1) 
2  
(1-4) 
2 (1-8) 
>16  
(>16) 
2 
 (2-4) 
>32 
 (>32) 
A. baumannii 
CDH102 
1 
 (0.5-1) 
1  
(1) 
2 
 (0.5-2) 
>16  
(>16) 
1  
(1-2) 
>32  
(>32) 
 
 
